Last reviewed · How we verify
NCT06157060
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
trial testing circulating tumor DNA in Hepatocellular Carcinoma Resectable in 255 participants. Currently enrolling.
20 November 2026
Quick facts
| Lead sponsor | Zhujiang Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 255 |
| Start date | 20 November 2023 |
| Primary completion | 20 November 2026 |
| Estimated completion | 30 November 2028 |
| Sites | 7 locations across China |
Drugs / interventions tested
- circulating tumor DNA
Conditions studied
- Hepatocellular Carcinoma Resectable — all drugs for Hepatocellular Carcinoma Resectable →
Sponsor
Zhujiang Hospital
Who can join
Adults 18 to 75, any sex, with Hepatocellular Carcinoma Resectable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, et al · · 2025 · cited 6× · PMID 39920551 · DOI 10.1007/s10147-024-02683-0
Verify or expand the search:
- PubMed search for NCT06157060
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of circulating tumor DNA
Trials testing the same drug.
- NCT05601505 — Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer · Phase 2 · recruiting
Other Zhujiang Hospital trials
Trials by the same sponsor.
- NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
- NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
- NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
- NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
- NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06157060 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
- Last refreshed: 20 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06157060.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing